Nucleotide excision repair is a potential therapeutic target in multiple myeloma - Szalat, R; Samur, M K; Fulciniti, M; Lopez, M; Nanjappa, P; Cleynen, A; Wen, K; Kumar, S; Perini, T; Calkins, A S; Reznichenko, E; Chauhan, D; et al. (Leukemia, 2018)
Keywords: 13/1; 13/109; 13/89; 14; 14/35; 14/5; 14/63; 38; 38/39; 631/67/1059/99; 631/67/1990/804; Adducts; Alkylating agents; Alkylation; Cancer; Cancer Research; Care and treatment; Cell Line, Tumor; Complementation; Critical Care Medicine; Crosslinking; Deoxyribonucleic acid; DNA; DNA adducts; DNA helicase; DNA Helicases - genetics; DNA repair; DNA Repair - genetics; DNA-Binding Proteins - genetics; Drug development; Drugs; Gene expression; Gene sequencing; Genetic aspects; Health aspects; Hematology; Humans; Inhibition; Intensive; Internal Medicine; Life Sciences; Medicine; Medicine & Public Health; Multiple myeloma; Multiple Myeloma - genetics; Nucleotide excision repair; Oncology; Original; original-article; Repair; Ribonucleic acid; Risk factors; RNA; RNA-mediated interference; Sensitivity; Sensitivity analysis; Transcription; Transcription, Genetic - genetics; Xeroderma pigmentosum; Xeroderma Pigmentosum - genetics